Pharmaceuticals

Government Initiatives Drive Growth In Pegfilgrastim Biosimilars Market Is Supporting Development Across The Pegfilgrastim Biosimilars Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Pegfilgrastim Biosimilars Market Increase Between 2026 And 2030?

The pegfilgrastim biosimilars market size has experienced strong growth in recent years. It is anticipated to increase from $1.92 billion in 2025 to $2.04 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This historical growth can be linked to the high cost of originator pegfilgrastim, limited availability of biosimilars, a growing cancer patient population, increasing chemotherapy procedures, and rising awareness of neutropenia management.

The pegfilgrastim biosimilars market is anticipated to show robust expansion over the coming years. It is projected to expand to $2.65 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.7%. This projected growth is driven by the introduction of novel biosimilars, a greater uptake in supportive oncology settings, the enlargement of hospital and retail pharmacy networks, governmental initiatives promoting biosimilar use, and increasing financial commitments to stem cell transplantation therapies. Significant trends during this period involve the increasing integration of pegfilgrastim biosimilars into supportive cancer care, the broadening of hospital and retail pharmacy distribution routes, a heightened priority on alleviating chemotherapy-induced neutropenia, an expansion in hematopoietic and peripheral blood stem cell transplantation applications, and augmented investments in managing chronic and severe congenital neutropenia.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

What Key Growth Drivers Are Influencing The Pegfilgrastim Biosimilars Market?

Government efforts aimed at developing biosimilars are anticipated to propel the pegfilgrastim biosimilars market. Globally, governments are prioritizing biosimilar development due to their economical benefits. The US Food and Drug Administration (FDA) introduced a Biosimilar Action Plan to expand treatment options. The Australian government is dedicated to the Biosimilar Awareness Initiative, reinforcing this commitment by providing a $5 million grant to the Generic and Biosimilar Medicines Association. This funding supports enhanced general biosimilar education and activities that encourage the appropriate dispensing, prescription, and utilization of biosimilar medicines. As a result, these governmental initiatives for biosimilar development contribute to increased production and awareness, which subsequently fosters the growth of the pegfilgrastim biosimilars market.

What Key Segment Areas Are Included In The Pegfilgrastim Biosimilars Market Assessment?

The pegfilgrastim biosimilars market covered in this report is segmented –

1) By Application: Chemotherapy Treatment, Transplantation, Other Applications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

3) By Route of Administration: Prefilled Syringes (PFS), On-body Injectors (OBI), Other Routes

Subsegments:

1) By Chemotherapy Treatment: Supportive Care for Cancer Patients, Reduction of Chemotherapy-Induced Neutropenia

2) By Transplantation: Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

3) By Other Applications: Treatment of Chronic Neutropenia, Treatment of Severe Congenital Neutropenia

Which Trends Are Supporting The Evolution Of The Pegfilgrastim Biosimilars Market?

Major companies active in the pegfilgrastim biosimilars market are concentrating on technological innovation in biopharmaceuticals, such as developing high-quality biosimilars to offer safe, effective, and readily available alternatives to original biologic therapies for cancer patients. High-quality biosimilars are defined as biologic drugs that closely mirror the reference product in terms of structure, function, safety, and efficacy. For instance, in February 2023, Fresenius Kabi, a Germany-based healthcare company specializing in pharmaceuticals and medical technologies, launched Stimufend, its first pegfilgrastim biosimilar in the U.S. Stimufend helps prevent and treat chemotherapy-induced neutropenia and is provided as a 6 mg/0.6 mL solution in a single-use pre-filled syringe equipped with a built-in needle guard. By combining advanced biosimilar development with user-friendly delivery, Stimufend represents a technological progression in making high-quality biologic therapies more accessible.

Which Companies Are Influencing The Pegfilgrastim Biosimilars Market?

Major companies operating in the pegfilgrastim biosimilars market are Amgen, Mylan N.V., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Biocon, Pfizer, Celltrion Healthcare, Coherus BioSciences, Gedeon Richter, Fresenius Kabi, Hetero Labs, Intas Pharmaceuticals, LG Chem, Merck KGaA, Zydus Cadila, Aurobindo Pharma, Apotex Inc., Dr. Reddy’s Laboratories, Stada Arzneimittel AG, Shanghai Henlius Biotech, Alvotech, EirGenix, Kye Pharmaceuticals, CinnaGen, Boryung Pharmaceutical, Sinopharm

Access The Complete Pegfilgrastim Biosimilars Market Report:

https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

Which Area Represents The Largest Portion Of The Pegfilgrastim Biosimilars Market?

North America was the largest region in the pegfilgrastim biosimilars market in 2025. Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pegfilgrastim Biosimilars Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=4015&type=smp

Browse Through More Reports Similar to the Global Pegfilgrastim Biosimilars Market 2026, By The Business Research Company

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Oncology Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report

Oral Biologics And Biosimilars Market 2026

https://www.thebusinessresearchcompany.com/report/oral-biologics-and-biosimilars-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795